Interventional Cardiology
In the rapidly evolving world of cardiology, our interventional cardiology program leads the field with advancements in care, research, and education initiatives.
Reshaping the future of heart care
2025 Outcomes
Our interventional cardiology team is transforming patient outcomes with advanced technology and minimally invasive techniques. Procedures such as angioplasty and stenting, along with structural heart interventions, are redefining modern medicine. As the demand for precision and safety increases, interventional cardiology continues to lead in enhancing heart care, extending and improving the quality of life for thousands in North Texas and beyond each year.
PCI volumes and outcomes across the enterprise
- We are a major referral center for high-risk PCI (including left main and CTO cases) with patients sent from all over Texas, Oklahoma, Louisiana and further.
- We utilized imaging guidance for enhanced precision in over 60% of all percutaneous coronary interventions (PCIs), compared to a national average of less than 20%.
- Over 3,600 cases across the enterprise utilized IVUS and OCT last year, including diagnostics.
- We increased the use of coronary physiology and functional angiography (FFR Angio), conducting 527 cases last year.
| Procedure | Volume | Mortality | Major Adverse Coronary Event (NCDR) | ||
|---|---|---|---|---|---|
| Enterprise | National Average | Enterprise | National Average | ||
| PCI | >4,600 | 1% | 1.9% | 1.1% | 2.52% |
| CTO | 350+ PER YEAR | 0.8% | – | – | – |
All data April 2024–March 2025
Accomplishments
- Our Plano location started a dedicated chest pain clinic to cater to patients with angina, including ANOCA and MINOCA.
- Our Dallas campus was the first in Texas and fifth in the U.S. to perform a commercial drug-coated balloon procedure, innovating interventional cardiology by combining balloon angioplasty with targeted drug delivery to prevent restenosis without permanent implants.
- The study, “Comparative Outcomes of Left Main and Non-Left Main Percutaneous Coronary Intervention from the Excellence in Coronary Artery Disease (XLCAD) Registry,” was published in the April 2025 issue of The American Journal of Cardiology from our database of real-world outcomes. Additionally, XLPAD serves as a national registry for interventional cardiologists and surgeons to collaborate on peripheral arterial disease, functioning as a Medicare quality database that enables real-time data collection and analysis from 16 hospitals across the U.S. Subash Banerjee, MD, founded both databases.
- Our Dallas and Plano locations have been at the forefront of leading renal denervation clinical trials that led to FDA approval. Notably, Dallas performed the first commercial case in Texas and the second in the U.S.
- A new biorepository has been established to support advanced cardiovascular research, containing over 10,000 blood specimens from participants in NIH-funded clinical trials. Funded by a grant from Novartis, the initiative focuses on analyzing lipoprotein(a) [Lp(a)] levels and their association with cardiovascular outcomes. This collaborative effort aims to enhance our understanding of Lp(a) as a potential biomarker and therapeutic target in cardiovascular disease.
- We launched a coronary physiology program in Fort Worth with an emphasis on coronary microvascular dysfunction
CathPCI Volumes
2000
1600
600
0
FY23
FY24
Plano/MCKINNEY
FY23
FY24
DENTON
Srinivasa P. Potluri, MD
Chairman, Cardiovascular Medicine
Karim M. Al-Azizi, MD
Medical Director, Cardiac Catheterization Laboratory
ON THE HORIZON
We are building in-house research capabilities to empower current and future PIs with source data that resides within our system. This also allows for easier grant funding and fundraising and will help drive future AI and machine learning.
28 live cases broadcast last year to global audiences, an educational tool that enables healthcare professionals to observe complex procedures, learn new techniques and interact with experts via Q&A sessions.
Innovation
Our physicians and researchers embrace advanced technologies in pursuit of precision PCI.
In a move to foster innovation in cardiology education, Subhash Banerjee, MD, editor-in-chief of The American Journal of Cardiology, recently launched a new section titled Applied Clinical Evidence. This initiative aims to empower the next generation of cardiologists by encouraging fellows to identify unique clinical cases and submit their studies for publication, bridging the gap between academic learning and real-world practice.
Quality Awards 2025
Achievements placing us among the elite
Heart & Vascular Surgery
Denton: 3 Stars in 2 Categories
Denton
Previous
Next